MilliporeSigma, the life science business of Merck KGaA, has completed its $600-million acquisition of Mirus Bio, a Madison, Wisconsin-based life-sciences company.   

Mirus Bio, part of Gamma Biosciences, a life-sciences tools platform created by the investment firm, KKR, specializes in the development and commercialization of transfection reagents, such as TransIT-VirusGEN. Transfection reagents play a role in producing viral vector-based gene therapies. Mirus Bio’s transfection reagents complement MilliporeSigma’s upstream bioprocessing portfolio 

Source: MilliporeSigma